Scholar Rock Holding Corporation (NASDAQ:SRRK) Insider Sells $828,833.04 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) insider Mo Qatanani sold 24,066 shares of Scholar Rock stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $34.44, for a total value of $828,833.04. Following the completion of the sale, the insider directly owned 115,495 shares in the company, valued at $3,977,647.80. This represents a 17.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Scholar Rock Stock Performance

NASDAQ SRRK traded down $0.68 during trading on Friday, reaching $37.44. 687,816 shares of the company's stock were exchanged, compared to its average volume of 1,303,407. The business has a 50 day moving average price of $32.78 and a 200-day moving average price of $35.11. The stock has a market capitalization of $3.55 billion, a P/E ratio of -14.80 and a beta of 0.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.25 and a quick ratio of 10.25. Scholar Rock Holding Corporation has a fifty-two week low of $6.76 and a fifty-two week high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same period in the previous year, the business earned ($0.59) earnings per share. Sell-side analysts forecast that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Scholar Rock

A number of institutional investors have recently bought and sold shares of the business. CWM LLC grew its position in shares of Scholar Rock by 152.8% in the first quarter. CWM LLC now owns 996 shares of the company's stock valued at $32,000 after purchasing an additional 602 shares during the last quarter. Federated Hermes Inc. acquired a new position in shares of Scholar Rock in the first quarter valued at approximately $71,000. GF Fund Management CO. LTD. grew its position in shares of Scholar Rock by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company's stock valued at $77,000 after purchasing an additional 430 shares during the last quarter. Strs Ohio acquired a new position in shares of Scholar Rock in the first quarter valued at approximately $77,000. Finally, AlphaQuest LLC grew its position in shares of Scholar Rock by 490.7% in the first quarter. AlphaQuest LLC now owns 5,417 shares of the company's stock valued at $174,000 after purchasing an additional 4,500 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SRRK. Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Wedbush reaffirmed an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Wednesday, June 18th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.